Oncology & Haematology最新文献

筛选

英文中文

Tailoring the Treatment of Early-stage HER2-positive Breast Cancer: One Size Does Not Fit All 调整早期her2阳性乳腺癌的治疗:一种方法不适合所有人

Oncology & Haematology Pub Date : 1900-01-01 DOI: 10.17925/ohr.2023.19.1.11

I. Schlam, P. Tarantino, A. Waks, S. Tolaney

{"title":"Tailoring the Treatment of Early-stage HER2-positive Breast Cancer: One Size Does Not Fit All","authors":"I. Schlam, P. Tarantino, A. Waks, S. Tolaney","doi":"10.17925/ohr.2023.19.1.11","DOIUrl":"https://doi.org/10.17925/ohr.2023.19.1.11","url":null,"abstract":"Human epidermal growth factor receptor-2 (HER2)-positive breast cancer accounts for 15% of all breast cancers and this cancer subtype was historically associated with poor outcomes. The development of HER2-directed therapies has dramatically improved outcomes for patients with early and advanced HER2+ disease. Trastuzumab is a HER2-targeted monoclonal antibody first approved for the treatment of advanced breast cancer in the late 1990s. Since then, it has been shown to improve long-term outcomes for patients with early-stage disease, particularly when given in combination with chemotherapy in the (neo)adjuvant setting. Pertuzumab is another monoclonal antibody that targets a different domain of the HER2 receptor from trastuzumab and prevents HER2–HER3 dimerization. The addition of pertuzumab to trastuzumab and chemotherapy improved long-term outcomes for patients with advanced disease; this drug has also been studied in the (neo)adjuvant setting and proved to improve long-term outcomes for patients with lymph node involvement. Neratinib and trastuzumab emtansine in the adjuvant setting have been shown to improve outcomes for selected high-risk patients. As more effective treatment options have been developed for the treatment of HER2+ breast cancer, we have progressively moved from a one-size-fits-all approach towards a tailored paradigm. In this narrative review, we summarize the diagnosis and prognosis of early-stage HER2+ breast cancer, as well as current treatment approaches.","PeriodicalId":249239,"journal":{"name":"Oncology & Haematology","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116245121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cholangiocarcinoma: The Present and Future of Targeted Therapies 胆管癌:靶向治疗的现在和未来

Oncology & Haematology Pub Date : 1900-01-01 DOI: 10.17925/ohr.2022.18.1.9

A. Kalyan, R. Shroff

引用次数: 0

首页上一页

Oncology &amp; Haematology最新文献

Oncology & Haematology最新文献